Popular Gemcitabine News and Current Events | Page 5

Popular Gemcitabine News and Current Events, Gemcitabine News Articles.
Sort By: Most Relevant | Most Recent
Page 5 of 6 | 208 Results
Inhibiting Hedgehog signaling pathway may improve pancreatic cancer treatment
Combining a new targeted therapy with standard chemotherapy may help defeat pancreatic cancer, according to results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held June 18-21. (2012-06-19)

Study finds that only half of a commonly used cancer drug is activated in cancer patients
According to results reported at the 40th Annual Meeting of the American Society of Clinical Oncology, only half of the delivered dose a commonly used chemotherapeutic agent may be activated in cancer patients. The study analyzed data from 31 cancer patients given 30-minute infusions of gemcitabine and found that while approximately 50 percent of the dose was likely to be converted to active metabolites, the other 50 percent was likely to be inactivated. (2004-06-08)

New analysis helps guide use of erlotinib in advanced non-small cell lung cancer
Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland. (2012-04-18)

New trick for 'old' drug brings hope for pancreatic cancer patients
Scientists have found a new use for an old drug by showing that it shrinks a particular type of pancreatic cancer tumor and stops it spreading. (2014-08-03)

TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients
Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new drug combination consisting of a standard drug called gemcitabine and a drug called nab-paclitaxel for patients with advanced pancreatic cancer. The study results are published in the prestigious Journal of Clinical Oncology. (2011-10-04)

Marimastat produces comparable survival rates to chemotherapy in some advanced pancreatic cancer patients
An international team of researchers from the United States and Britain report that marimastat offers a similar survival benefit to chemotherapy in patients with non-metastatic pancreatic cancer, but with fewer side effects. A randomized clinical trial compared the effects of three different doses of marimastat, a matrix metalloproteinase inhibitor, with gemcitabine in 414 patients with advanced pancreatic cancer. (2001-07-30)

UCLA cancer scientists identify liposarcoma tumors that respond to chemotherapy
Using a strategy that tracks cancer cells' consumption of nucleosides, a team of researchers at UCLA's Jonsson Comprehensive Center has identified a group of liposarcoma tumors that can be imaged by PET scanning using a tracer substance known as FAC. Furthermore, they have found that these tumors are sensitive to chemotherapy. (2012-12-10)

Mayo Clinic: Nutritional supplement works against some pancreatic cancer cells in mice
The dietary supplement gamma-linoleic acid can inhibit the growth of a subset of pancreatic cancer cells and selectively promote cancer cell death in mice, a Mayo Clinic study has found. (2012-04-03)

Jefferson researcher receives 2010 Pancreatic Cancer Action Network-AACR Career Development Award
Molecular biologist Jonathan Brody, Ph.D., assistant professor, department of surgery at Jefferson Medical College of Thomas Jefferson University, has been awarded a 2010 Pancreatic Cancer Action Network -- American Association of Cancer Research Career Development Award in memory of Skip Viragh. This two-year grant awards $200,000 to Dr. Brody to help support his innovative research in pancreatic cancer. He will receive recognition for his work at the 2010 AACR annual meeting in Washington, D.C., on April 20. (2010-04-13)

FDA approves drug tested by Scottsdale Healthcare and TGen
Abraxane, the brand name for nab-paclitaxel, was approved for use in combination with gemcitabine, the previous standard drug therapy, following a large scale international clinical trial headed by Dr. Daniel D. Von Hoff, TGen Physician-in-Chief and Chief Scientific Officer at Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and TGen. (2013-09-06)

EORTC intergroup trial opens for patients with resected head of pancreas adenocarcinoma
EORTC trial 40084-22084 has two primary objectives: To determine if adding erlotinib to gemcitabine adjuvant chemotherapy will improve survival as compared to gemcitabine alone following resection of head of pancreas adenocarcinoma, then, following adjuvant chemotherapy, to determine if concurrent fluoropyrimidine and radiotherapy improves survival for patients who have no evidence of progressive disease. (2013-06-04)

Gemcitabine demonstrates promise as a low toxic chemotherapeutic agent for bladder cancer
Patients with bladder cancer could benefit from treatment with gemcitabine (Gemzar®), a chemotherapeutic agent that has been used successfully to treat pancreatic cancer and non-small cell lung cancer, according to phase I trial results reported at the 38th Annual Meeting of the American Society for Clinical Oncology (ASCO) by Merrill J. Egorin, M.D., professor of medicine at University of Pittsburgh Cancer Institute. (2002-05-19)

Combination therapy may improve survival for pancreatic cancer
Patients with pancreatic cancer, a historically difficult-to-treat cancer with poor survival rates, may benefit from treatments studied in an international, multi-center research trial. (2006-07-25)

Lung cancer patients with diabetes show prolonged survival
Lung cancer patients with diabetes tend to live longer than patients without diabetes, according to a Norwegian study published in the November issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer. (2011-10-17)

New drug candidate prolongs the lives of pancreatic cancer patients
The new drug compound Salirasib, developed at Tel Aviv University, has shown positive results against pancreatic cancer and recently passed Phase I/II clinical trials. The drug, given in combination with gemcitabine, the standard drug used to combat pancreatic cancer, almost doubled the life expectancy of those who received it. (2009-07-20)

Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs
A University of Minnesota research team has developed a new delivery system for a combination of two FDA approved drugs that may serve as an effective treatment for the human immunodeficiency virus. The discovery, which allows for a combination of decitabine and gemcitabine to be delivered in pill form, marks a major step forward in patient feasibility for the drugs, which previously had been available solely via injection or intravenous therapy. (2013-08-30)

Improving chemotherapy effectiveness by acting on the immune system
An Inserm team in Dijon directed by François Ghiringhelli is to publish an article this week in the Nature Medicine review. The article suggests that two chemotherapy drugs frequently used to treat digestive and breast cancers may encourage the development of tumors by modulating the anti-tumoral immune response. (2012-12-04)

Chemotherapy drug improves survival following surgery for pancreatic cancer
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for six months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in the Oct. 9 issue of JAMA. (2013-10-08)

FDA approves new therapy for pancreatic cancer patients
Patients with advanced pancreatic cancer now have access to the new FDA approved drug, Onivyde, that produced significant overall survival rates in an international clinical study conducted in part by researchers at HonorHealth Research Institute and the Translational Genomics Research Institute. (2015-10-26)

Hutchinson Center scientists break through pancreas cancer treatment barrier
Pancreas cancer tumors spread quickly and are notoriously resistant to treatment, making them among the deadliest of malignancies. Their resistance to chemotherapy stems in part from a unique biological barrier the tumor builds around itself. Now scientists at Fred Hutchinson Cancer Research Center have found a way to break through that defense, and their research represents a potential breakthrough in the treatment of pancreas cancer. (2012-03-19)

M. D. Anderson study first to evaluate prevalence, impact of off label chemotherapy in breast cancer
At some point during their care, more than one-third of metastatic breast cancer patients receive chemotherapy off label, the legal use of FDA-approved drugs in a different indication than for which they were approved, according to researchers at the University of Texas M. D. Anderson Cancer Center. (2009-05-14)

Avantogen and Innovate announce ASCO abstracts
Avantogen Limited ( (2006-06-08)

After resection, common treatment of pancreatic cancer as effective as chemotherapy drug dose
Use of gemcitabine, a drug that can be effective in treating advanced and resected pancreatic cancer, did not result in improved overall survival after pancreatic cancer resection (surgical removal) compared to patients who received fluorouracil and folinic acid, another treatment regimen that has shown effectiveness, according to a study in the Sept. 8 issue of JAMA. (2010-09-07)

Clinical trial tests COXEN model to predict best treatment for bladder cancer
A computer model, COXEN, matches cancer genetics to best treatments. It is now in a national clinical trial for bladder cancer. (2014-08-13)

TGen's Dr. Daniel Von Hoff delivers first Lori Groetken Memorial Lecture
Dr. Daniel Von Hoff, Physician-In-Chief of the Translational Genomics Research Institute is the first recipient of the Lori Groetken Memorial Lecture and Award. Dr. Von Hoff's lecture, (2012-10-04)

Death, division or cancer? Newly discovered checkpoint process holds the line in cell division
Researchers from Fox Chase Cancer Center and Technion-Israel Institute of Technology in Haifa, Israel, have discovered a novel biochemical activity involved in controlling cell division, which they've called the mitotic checkpoint factor 2. While the proteins involved in MCF2 remain to be determined, their findings offer insight into a fundamental question of biology, which may also help to increase the efficiency of cancer drugs like gemcitabine or paclitaxel. (2008-07-01)

Penn researchers uncover novel immune therapy for pancreatic cancer
Researchers at the University of Pennsylvania's Abramson Cancer Center have discovered a novel way of treating pancreatic cancer by activating the immune system to destroy the cancer's scaffolding. The strategy was tested in a small cohort of patients with advanced pancreatic cancer, several of whose tumors shrank substantially. The team believes their findings - and the novel way in which they uncovered them -- could lead to quicker, less expensive cancer drug development. The findings are published in the March 25 issue of Science (2011-03-24)

Response to preoperative therapy may predict survival in pancreatic cancer patients
New research from Fox Chase Cancer Center finds that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, as those whose tumors respond least. (2010-05-28)

Study finds CT scans predict chemotherapy response in pancreatic cancer
Computed tomography scans routinely taken to guide the treatment of pancreatic cancer may provide an important secondary benefit. According to new research from the University of Texas MD Anderson Cancer Center, the scans also reflect how well chemotherapy will penetrate the tumor, predicting the effectiveness of treatment. (2014-03-11)

Best care for the oldest lung cancer patients
Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce. Now Italian oncologists are conducting a number of trials targeting elderly patients with non-small cell lung cancer, and offer a review of the latest findings -- and their recommendations -- in the current issue of Therapeutic Advances in Medical Oncology, published by SAGE. (2010-04-29)

New drug substantially extends survival in pancreatic cancer
A new form of chemotherapy that destroys new blood vessels that grow around tumors has produced excellent results in a phase II trial of patients with inoperable pancreatic cancer, researchers report at the 33rd Congress of the European Society for Medical Oncology in Stockholm. (2008-09-16)

Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients
Amid the controversy surrounding the Food and Drug Administration's ruling that Avastin should no longer be used to treat metastatic breast cancer, a new multinational Phase III clinical trial shows that Avastin significantly increased tumor response rates in breast cancer patients when given before surgery. (2011-08-23)

Bladder-sparing treatment shows promise against cancer, maintains quality of life, UMHS study finds
A new pilot study by University of Michigan Health System researchers found combining radiation therapy and the chemotherapy drug gemcitabine may effectively treat bladder cancer without toxic reactions, while allowing many patients to preserve their bladder. (2004-07-20)

Moffitt Cancer Center: Growing interest in prognostic test for non-small cell lung cancer
Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for non-small lung cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer. (2010-04-26)

2-drug combination, nab-paclitaxel and gemcitabine, improves survival in pancreatic cancer
Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology, have participated in an international phase III study, published in The New England Journal of Medicine. Results show that administering these two drugs in combination significantly improves one- and two-year survival in patients with advanced pancreatic cancer versus gemcitabine alone, the first-line treatment or most standard approach for this type of cancer to date. (2013-10-17)

RTOG initiates a phase I trial testing the therapy ganitumab for locally advanced pancreatic cancer
Conducted by the Radiation Therapy Oncology Group, the results of the RTOG 1102 are expected to provide important dosing and safety information needed prior to advancing ganitumab evaluation to a phase II randomized trial. (2011-12-14)

New treatment for pancreatic cancer allows life-saving surgery
A new treatment for pancreatic cancer developed by clinical researchers of Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center substantially reduces the size of tumors and lowers the risk of local recurrence of the disease. (2005-12-06)

Multicenter study underscored the need of a uniform approach to the treatment of BCa
A new study, involving eight Italian research centers, concluded that an aligned approach to the treatment of advanced bladder cancer is much needed, while confirming previously published results on survival estimates of associated salvage therapies. (2013-11-15)

Newer lung cancer treatments extend survival longer than traditional regimens
Patients with advanced non-small cell lung cancer who are treated with regimens containing paclitaxel and carboplatin survive longer than patients treated with older cisplatin-based regimens or supportive care, a new study finds. (2002-06-27)

Combination treatment improves survival for pancreatic cancer
A combination of chemotherapy drugs could double survival rates for pancreatic cancer, suggests a study published online today by The Lancet Oncology. (2005-05-09)

Page 5 of 6 | 208 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.